GlassScriptPhysician profile
Deborah A Bordonaro
NPI 1770801599
$2,468.28
in general payments reported to CMS, 2019-2025
21 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,970 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.38 | 2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $357.33 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $190.73 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $178.19 | 2024-2025 | |
| Amgen INC. | $150.15 | 2024-2025 | Otezla, Repatha, Otezla |
| Braeburn INC. | $148.36 | 2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.75 | 2024-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $60.55 | 2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $39.27 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.73 | 2024 | Xifaxan, Trulance |
| Abbott Laboratories | $30.96 | 2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $30.01 | 2024 | Zoryve |
| Daiichi Sankyo INC. | $27.96 | 2024 | Injectafer |
| Lilly USA, LLC | $27.38 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $25.51 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.82 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $21.44 | 2024 | Korlym |
| Abbvie INC. | $18.21 | 2024 | |
| Avvisto Therapeutics, LLC | $16.28 | 2024 | Cycloset |
| Radius Health, INC. | $15.62 | 2024 | Tymlos |
| Esperion Therapeutics, INC. | $14.65 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Bordonaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.